IND Expansion Target Nesteds NST-628 IND clearance as a gateway to collaboration or sponsored trials with CROs and biopharma partners pursuing pan-raf/mek or precision oncology assets.

Financing Momentum Leverage their recent $90M Series A and multi-year funding trajectory to propose co-development, milestone-based partnerships, or value-added services aligned with early-stage to clinical-stage hematology/solid tumor programs.

Collaboration Value Highlight HitGen partnership and DNA-encoded library capabilities as a doorway for research collaborations, access to diverse chemistries, and accelerated hit-to-lead programs for novel oncology targets.

Precision Focus Position offerings around precision oncology and matched patient-fit therapeutics to align with Nested’s mission, regulatory pathways, and potential companion diagnostic opportunities.

SMB to Mid-market Capitalize on Nested’s lean team size (11-50) and growth stage by proposing scalable outsourcing, advisory, and modular platform services that reduce time-to- IND filing and development risk for smaller biotechs.